Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuronal PAS domain-containing protein 3 (NPAS3) is a member of the basic helix-loop-helix-PAS (bHLH-PAS) family of transcription factors, primarily expressed in the nervous system[1][2][3]. NPAS3 forms obligate heterodimers with the aryl hydrocarbon receptor nuclear translocator (ARNT), and together these complexes regulate transcription of specific target genes through direct DNA binding[1][3]. NPAS3 plays an important role in neurodevelopment, adult neurogenesis, and regulation of neural cell proliferation and apoptosis[1][2]. Genetic studies link NPAS3 mutations or altered function to neuropsychiatric conditions such as schizophrenia, autism spectrum disorder, and bipolar disorder[3]. Although its druggability potential is highlighted by the multi-ligand-binding architecture of the bHLH-PAS family, there are currently no known drugs directly targeting NPAS3[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuronal PAS domain-containing protein 3 (NPAS3).